A vaccine order, a population moved out of managed care, and a Board in session

The order recognises a set of “Gold Standard Childhood Vaccine Recommendations” informed by three distinct categories of childhood immunization recommendation identified in an HHS scientific assessment. That assessment was completed under the executive order of 5 December 2025 on aligning United States core childhood vaccine recommendations with best practices from peer, developed countries; it identified a set of consensus vaccines consistently recommended in all peer countries and found that the United States recommends more childhood vaccines than any peer nation, including more than twice as many doses as some European nations. The accompanying White House fact sheet describes the recommendations as covering 11 diseases — a decrease, in its own comparison, from the 18 it says CDC recommended in 2024 — with immunizations no longer recommended for all children moved to shared clinical decision-making.

On the combination measles, mumps and rubella vaccine the order states that MMR should be administered as three separate single-disease shots once such products are domestically available, and that to the maximum extent feasible all childhood immunizations should be administered at separate medical visits. It directs the HHS Task Force on Safer Childhood Vaccines to present plans to the President, within 90 days, to offer options to administer core childhood vaccines — starting with MMR — as single vaccines rather than combination products.

For a family-medicine practice the operative question is not what the order recommends but what a parent will ask about it, and the honest answer has two halves. The single-antigen route the order prefers for MMR does not exist to prescribe: the order conditions it on such products being domestically available, and directs planning toward that availability rather than establishing it. Separate-visit administration is different — that is a scheduling question a practice can be asked to accommodate now, and it multiplies visits for the same protection, which makes it a conversation about transport, time off work and missed school as much as about immunology. The 8 November plan date is the next point at which this produces a document.

Federal guidance issued in 2025 directed every state to move Medicaid members with unsatisfactory immigration status out of risk-based managed care and into fee-for-service by 1 January 2027, on the basis that states may not cover federally eligible emergency Medicaid services for this population through risk-based managed care. California is implementing it: from that date these members, including dual-eligible members, receive all covered Medi-Cal services through fee-for-service.

DHCS’s provider guidance is specific. A provider must be enrolled in Medi-Cal fee-for-service to be paid for treating these patients; a provider not already enrolled through PAVE must submit an application and be approved by 1 January 2027 to receive fee-for-service rates. Members will no longer be assigned a primary care provider, but an enrolled provider may continue seeing the same patients. Enhanced Care Management and Community Supports are not covered under fee-for-service; DHCS states that care management, care coordination, case management and community health worker services remain billable under existing fee-for-service codes, and that it will publish the code lists. Providers are advised to have patients refill prescriptions before 1 January 2027. The May Revision scored the change as a reduction of $583.8 million ($471.6 million General Fund) in 2026–27 and $1.5 billion ($1.2 billion General Fund) ongoing; the enacted budget included $39 million General Fund in 2026–27 for care coordination and navigation.

This is the change most likely to sever an existing doctor–patient relationship in a Central Valley practice, and it does so through an enrollment form rather than a coverage decision. The patient keeps Medi-Cal; what changes is the delivery system, and with it whether the practice can be paid. A physician who sees these patients under a managed-care contract and is not separately enrolled in fee-for-service becomes, on 1 January 2027, an unpaid provider to a patient who is still covered — which in practice means the patient is told to go elsewhere. The second-order loss is care management: ECM and Community Supports end for this population, and the substitute is a set of billing codes a small practice has to know how to use. The date that matters to a clinic is therefore not January but whenever its application must be filed to be approved in time.

The Medical Board of California is in session. Panel A convened at 9:00 a.m. for public oral argument on a non-adopted proposed decision followed by closed-session deliberation; Panel B sits this afternoon; the quarterly Board meets tomorrow and Friday, carrying the eighteen legislative positions and the licensing and enforcement reports covered in the 15 August issue and the Board tracker.

Nothing that happens in a panel’s closed session is knowable today, and this page does not guess. Outcomes populate from the webcast record, the official action summary or approved minutes — whichever the Board publishes first.

The items with statewide reach sit on tomorrow’s agenda: the Board’s positions on pending legislation including the physician wellness program bill, and its response to the enforcement-timeline audit. Today’s panels decide individual disciplinary matters.

A third state joins the OIG’s Medicaid managed-care prior-authorisation audit series — and this one cuts the other way. Where the Kansas and New York audits found state oversight failures, OIG’s Louisiana audit found the managed-care organisation generally complied with federal and state process requirements when denying prior-authorisation requests. The report appears on OIG’s own index; the index page does not carry its issue date, which is therefore not restated here.

The series now has a spread — two states with findings, one generally compliant — which is what makes it an audit program rather than an indictment. For physicians the operational meaning is unchanged: process compliance is what these audits test, not whether any individual denial was clinically right.

The MHRA’s position is that microbiome-based medicinal products — medicines that modulate, restore or replace the human microbiome — fall within the existing framework of the Human Medicines Regulations 2012: as biological medicinal products, or in some cases as advanced therapy medicinal products. No MBMP currently holds a UK marketing authorisation. The paper sets out what developers must address — product characterisation, manufacturing consistency, batch-to-batch variability, safety assessment including antimicrobial-resistance risk, and clinical evidence — and leaves existing faecal microbiota transplantation arrangements (clinical trials, unlicensed supply under specials) unchanged.

For clinicians the near-term meaning is what did not change: FMT for recurrent C. difficile continues under the same arrangements and the same prescriber responsibility. The forward meaning is a licensing route: a class of therapies aimed at antimicrobial resistance now has a stated path to authorisation rather than a regulatory vacuum.

The TGA is consulting on letting automated systems process applications to change listed medicines — the low-risk, self-certified tier of Australia’s register, where products enter the ARTG on sponsor certification rather than individual pre-market evaluation. The proposal concerns the agency’s own administrative processing.

This is government process automation, not clinical AI: no diagnostic tool, no clinical decision support, no patient-facing system is regulated by it. Its interest is comparative — a medicines regulator formalising when its own decisions may be made by a machine, while the same agency regulates AI in medical devices by intended purpose.

FDA hosts a hybrid public meeting to hear from patients and care partners about nonhealing chronic wounds: daily-life effects, current treatment approaches, and what patients weigh before joining a clinical trial. Three sessions, each opening with a patient panel. Written comments run to 26 October.

Chronic wounds sit at the intersection of diabetes, vascular disease, primary care, podiatry and geriatrics, and the meeting’s output — patient-experience data — feeds endpoint design for future wound-therapy trials. For a family-medicine practice the relevance is who should speak: patients living with these wounds, and the clinicians who can help them register.

Health Canada authorised a Phase I trial of an mRNA vaccine candidate against Bundibugyo virus — the Ebola species driving the current outbreak in the Democratic Republic of the Congo, for which no licensed vaccine or treatment exists. Canada is the second country to authorise a Phase I Bundibugyo vaccine trial, after the UK. The study assesses safety, dose range and side effects in healthy participants. The company announced first vaccinations on 4 August; that is company material.

Nothing changes in any clinic. The record’s value is exactly what a Phase I authorization is: the earliest human-evidence stage, in a disease where the outbreak is outpacing the toolkit. If the candidate advances, later phases and any authorisation each require their own decision.

Dräger’s April 2026 Field Safety Notice expanded the population of Atlan anaesthesia workstations affected by a manufacturing defect that can cause piston ventilator failure before or during use — extending a notice first issued in October 2024. The MHRA’s direction: identify affected devices from the FSN listing, have the manufacturer replace the motor assemblies, and until then use affected devices only with permanent supervision. If mechanical ventilation fails — the device raises a ventilator-error alarm — transition immediately to manual or spontaneous ventilation.

These workstations ventilate adults, children and neonates under anaesthesia, which is why the mitigation is the story: no removal from service, but every listed theatre must staff for continuous supervision and be ready to hand-ventilate until its devices are corrected. That is a rota and drill question, and it lasts as long as the replacement queue.

The defect chapter this joins matters for reading it correctly: this is the second expansion of a 2024 correction, which says the affected population was underestimated — and the alert’s value is that it says so on the record.

In 2023, leakage and discolouration in Belzer organ-preservation solutions — the fluids that flush and store donated organs — meant potentially contaminated fluid and a risk of significant patient harm; advice issued, sales suspended. The 6 August update closes that file: corrective action by the manufacturer and UK responsible person is accepted, the suspension is lifted, and the MHRA’s review of its own data found no safety signals from the defect period.

The audience list shows the reach — critical care, general surgery, transplantation, renal medicine, cardiac and vascular surgery, paediatrics and neonatology. For those services the operational fact is a return to normal supply under updated instructions.

The record-keeping point is the lifecycle. The 2023 advice is not deleted; it is superseded by a named successor, and following the old advice is now itself the error. That is how a safety record should end: with its successor on the record, not with a disappearance.

Two entries joined the Canadian record in the window. A health product recall covers the Cook Medical Hemospray Kit — the powder used endoscopically to stop gastrointestinal bleeding — and a public advisory states that unauthorized drugs seized from a Montreal retailer may pose serious health risks. Both are recorded here at the level at which they were read: the index entry, its notice type and its date. The notices themselves are not summarised, so nothing is stated about affected lots, mechanism or distribution.

The distinction between the two is why they sit in one record. A recall of a hospital haemostasis device is a supply-and-substitution question for endoscopy services. An advisory about unauthorized product seized from a retailer is a consumer-exposure question — and products in that category are the ones a patient brings to a visit in a bag rather than on a medication list.